OvaScience Appoints Alison Lawton to Chief Operating Officer

  OvaScience Appoints Alison Lawton to Chief Operating Officer

Business Wire

CAMBRIDGE, Mass. -- January 2, 2013

OvaScience^SM, (OTC: OVSC), a life sciences company focused on the discovery,
development and commercialization of new treatments for infertility, announced
today the appointment of Alison Lawton to Chief Operating Officer. In
conjunction with this appointment, the Company’s current Chief Operating
Officer, Christopher Bleck, will assume the role of Chief Commercial Officer,
leading Sales and Marketing.

“We are pleased to welcome Alison and believe that her extensive experience in
directing global operations for Sanofi Biosurgery will enable her to make
significant contributions to OvaScience as we prepare for commercialization in
2014,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience.
“Alison’s leadership of the autologous cell therapy business, including
regulatory affairs, manufacturing and commercial in the U.S. and abroad, will
be important to OvaScience’s continued development of multiple therapies for

Ms. Lawton joins OvaScience from Sanofi Biosurgery (formerly Genzyme
Biosurgery), where she was Senior Vice President and General Manager,
responsible for three separate franchises, including surgical, cell therapy
and regenerative medicine, and orthopedics. She has more than 28 years of
global pharmaceutical and biotechnology experience, including 21 years at
Genzyme Corporation and seven years in the U.K. at Warner-Lambert/Parke-Davis.
Prior to Genzyme Biosurgery, Ms. Lawton was Senior Vice President of Global
Market Access for Genzyme, which involved leadership across several of
Genzyme’s global functional organizations including regulatory affairs and
corporate quality systems, policy programs, health outcomes and strategic
pricing, patient safety and risk management, and biomedical process excellence
and training. She served two terms as the industry representative on the U.S.
Food and Drug Administration (FDA) Cell & Gene Therapy Advisory Panel, and was
past President and Chair of Board of RAPS (Regulatory Affairs Professional
Society). Ms. Lawton is currently a Board member of Cubist Pharmaceuticals and
Verastem, Inc. She holds a B.Sc. Hons. in Pharmacology from King’s College

“OvaScience’s unique approach to developing next-generation treatments for
female infertility has the potential to improve the success of in vitro
fertilization and offers new options for patients who are unable to undergo
IVF,” said Ms. Lawton. “I am pleased to be joining a team that has already
demonstrated its ability to turn major scientific discoveries into product
candidates, and I am excited to be a part of bringing this to patients.”

About OvaScience

OvaScience (OTC: OVSC) is a life sciences company focused on the discovery,
development and commercialization of new treatments for infertility. The
Company’s patented technology is based on the discovery of egg precursor cells
(EggPC^SM), which are found in the ovaries. By applying proprietary technology
to identify and purify EggPCs, AUGMENT^SM aims to improve egg quality and
increase the success of in vitro fertilization (IVF). OvaScience’s team of
scientists, physicians and advisers includes recognized leaders in the field
of reproductive medicine. For more information, please visit

Forward-Looking Statements

This press release includes forward-looking statements about the Company’s
strategy, future plans and prospects, including statements regarding the
development of the Company’s product candidates, including AUGMENT^SM and
OvaTure^SM. Any statements in this release about our strategy, plans,
prospects and future expectations, financial position and operations, and
other statements containing the words “anticipate,” “believe,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” ”aim,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and similar
expressions, constitute forward-looking statements for the purposes of the
safe harbor provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors, including
risks related to: our expectations regarding the regulatory approvals required
for AUGMENT; the science underlying our two product candidates, which is
unproven; our ability to obtain, maintain and protect intellectual property
utilized by our products; our ability to obtain additional funding to support
our activities; our dependence on third parties; the successful development
of, and ability to obtain regulatory approval for, our product candidates;
competition from others; and our short operating history; as well as those
risks more fully discussed in the “Risk Factors” section of our most recently
filed Quarterly Report on Form 10-Q. The forward-looking statements contained
in this presentation reflect our current views with respect to future events.
We anticipate that subsequent events and developments will cause our views to
change. However, while we may elect to update these forward-looking statements
in the future, we specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as representing our view
as of any date subsequent to the date hereof.


OvaScience, Inc.
Theresa McNeely, 617-299-7356
Head of Corporate Communications
Press spacebar to pause and continue. Press esc to stop.